Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

Model improves accuracy in predicting hair loss effects.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Patient-reported hair improvements align with actual hair density changes, not hair width.

New tools and criteria have been developed to better assess and treat pediatric lupus.

The HAIR-Q is a reliable tool for assessing patient satisfaction with hair loss treatments.

Disease-specific tools better assess alopecia areata's impact on quality of life.

No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Skin disease activity scores can help decide when skin symptoms no longer affect the quality of life in patients with mild dermatomyositis.

New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.

Choosing the right recall period for patient feedback is important for accurate data and depends on the disease, symptom changes, and patient impact.

Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.

Hair follicles can be used to study gene expression and understand conditions like COPD.

The goal is to create a tool for patients to report their experiences with various hair and scalp disorders.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

The study aims to understand how mood, physical activity, light exposure, and seasonal changes affect sleep patterns.

Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.

Skin diseases are common and can significantly affect people's lives; better outcome measures and ethical clinical trials are needed to improve dermatology care.

Phosphorus homeopathy treatment led to complete hair regrowth in two Alopecia Areata patients.

Baricitinib is effective and safe for treating severe alopecia areata.

The Dermatology Life Quality Index is reliable and consistent but needs more diverse participant studies.

The instruments are valid but don't fully capture the emotional impact on adolescents with alopecia areata.

Injectable platelet-rich fibrin with microneedling is safe and effective for male hair loss but less supported than other treatments.

The Hair Check tool can measure hair loss, but patients' own reports are more reliable for assessing hair loss during chemotherapy.

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

CTCL patients can safely continue treatment during COVID-19 with proper safety measures.

Early diagnosis and treatment of discoid lupus erythematosus improve outcomes.

New tools were created to help lupus patients report their symptoms and impacts more accurately.